Lack of effective therapy of primary brain tumors has promoted the development of novel experimental approaches utilizing oncolytic viruses combined with gene therapy. Towards this end, we have assessed a conditionally replication-competent, g 1 34.5-deleted herpes simplex virus type 1 (HSV-1) expressing cytosine deaminase (CD) for treatment of malignant brain tumors. Our results are summarized as follows: (i) a recombinant HSV (M012) was constructed in which both copies of the g 1 34.5 gene were replaced with the bacterial CD gene, under the control of the cellular promoter Egr-1; (ii) M012-infected cells in vitro efficiently convert 5-fluorocytosine (5-FC) to 5-fluorouracil, thereby enhancing cytotoxicity of neighboring, uninfected cells; (iii) both direct and bystander cytotoxicity of murine neuroblastoma and human glioma cell lines after infection with M012 were demonstrated; (iv) direct intracerebral inoculation of A/J mice demonstrated lack of neurotoxicity at doses similar to G207, a g 1 34.5-deleted HSV with demonstrated safety in human patient trials and (v) intratumoral injection of M012 into Neuro-2a flank tumors in combination with 5-FC administration significantly reduced tumor growth versus tumors treated with R3659 combined with 5-FC, or treated with M012 alone. Thus, M012 is a promising new oncolytic HSV vector with an enhanced prodrug-mediated, antineoplastic effect that is safe for intracranial administration.
Introduction
Treatment of central nervous system (CNS) malignancies, particularly glioblastoma, has proven to be a formidable task. Malignant gliomas, the most common primary brain tumor in adults, have an estimated incidence of 15 000 new cases annually in the United States and are nearly universally fatal. Surgery, radiation and chemotherapy extend the median survival of these patients to 12-15 months, with only rare survivors at 5 years, a statistic that has not changed in 40 years. [1] [2] [3] The lack of therapeutic success and associated grim prognosis has encouraged exploration of novel molecular therapies for this disease. As 90% of gliomas recur locally, within 2 cm of their resection margin, and as systemic metastases are rare, these tumors are excellent targets for intervention with novel oncolytic viruses, including conditionally replicating herpes simplex viruses (HSV). 4 The neurovirulence phenotype of HSV has been mapped to the g 1 34.5 gene. 5 Genetically engineered HSV in which both copies of the g 1 34.5 gene have been deleted selectively replicate in tumor cells, but not in post-mitotic cells of the CNS, [6] [7] [8] thus making these suitable viral vectors for intracranial administration. These g 1 34.5-deleted (Dg34.5) HSV retain their antitumor efficacy in a wide variety of in vitro and in vivo gliomas and other tumor models, [9] [10] [11] and have produced long-term survival with tumor reduction in both syngeneic and xenogeneic murine tumor models of gliomas. 8, 10, [12] [13] [14] Another unique property of these Dg34.5 HSV-based vectors is their retained susceptibility to standard anti-HSV drugs like acyclovir.
A major limitation for use of genetically engineered HSV is that even multiple administrations of virus may not infect and destroy all tumor cells. To increase the oncolytic effects of genetically engineered HSV therapy, a new treatment paradigm has emerged where the construct is used as a vector for foreign expression, particularly of anti-neoplastic genes (Market et al. 15 and references therein). Foreign genes such as those encoding cytokines have been engineered into g 1 34.5-deleted HSV, and were demonstrated to increase the antitumor effects of the modified virus beyond its parent g 1 34.5-deleted HSV. [16] [17] [18] Although promising, the combined oncolytic activity and antitumor immune responses elicited by these cytokine-expressing viruses were unable to destroy uniformly all tumor cells in treated animals. Other HSV antitumor therapy strategies are under investigation to promote destruction of tumor cells, which have escaped both direct oncolytic activity and immune-mediated tumor killing.
Cytosine deaminase (CD), an enzyme found in some bacteria, fungi and viruses, but not in humans, converts non-toxic 5-fluorocytosine (5-FC) to highly toxic, chemotherapeutic agent 5-fluorouracil (5-FU), which disrupts RNA metabolism and blocks DNA synthesis by covalently binding thymidylate synthetase. 19, 20 5 -FU has been in clinical use since 1957, is a potent radiosensitizer and has been used as a single agent or in combination with other drugs for the treatment of a variety of solid tumors including malignant glioma, 21, 22 but has limitations as a systemically delivered agent secondary to induced toxicity.
CD/5-FC gene therapy produces 5-FU locally, decreasing the probability of systemic toxicity. Early studies demonstrated production of high levels of 5-FU when only a small percentage of tumor cells expressed CD. 21 Converted 5-FU freely diffuses from cells expressing CD to neighboring cells and does not require gap junctions, which may not be present in malignancy, to elicit bystander killing. 23, 24 We hypothesized that a conditionally replication-competent HSV engineered to express CD would also generate sufficient local concentrations of 5-FU after administration of the 5-FC prodrug to achieve bystander killing of malignant glioma cells, resulting in augmented virus-mediated oncolysis of these tumor cells.
Towards this end, we engineered a conditionally replication-competent, g 1 34.5-deleted HSV that expresses bacterial CD (M012) for the treatment of malignant brain tumors. We report the following: (i) M012 produces physiologically relevant concentrations of CD that is capable of converting 5-FC to 5-FU both in vitro and in vivo; (ii) M012 retains the ability to replicate in and directly lyse murine Neuro-2a neuroblastoma cells in vitro; (iii) addition of 5-FC significantly enhances M012 cytotoxicity in Neuro-2a cells; (iv) bystander killing of HSV-1-resistant GL261 tumor cells by M012 in the presence of 5-FC was demonstrated when these cells were co-cultured using higher ratios of the GL261-HIgR; (v) direct intracranial injection of M012 in mice that received intraperitoneal (i.p.) administration of 5-FC did not increase neurotoxicity above that of G207 HSV-1, a virus with demonstrated safety in humans; 25 and (vi) intratumoral (i.t.) injection of M012 into Neuro-2a flank tumors in mice combined with i.p. administration of 5-FC significantly reduced their growth rate versus tumors in mice treated with M012 only. These data warrant support for the use of Dg 1 34.5 HSV vectors as another conditionally replicating viral vector for delivery and expression of suicide genes that are safe for administration to malignancies arising in the brain.
Materials and methods

Cells
Vero cells, human 143 thymidine kinase (tk) cells and murine Neuro-2a neuroblastoma cell lines were all obtained from American Type Culture Collection (ATCC). Rabbit skin cells were originally obtained from J McClaren (University of New Mexico, Albuquerque, NM) and were grown as described previously.
17 GL261 tumor cells (C57BL/6 mice) were obtained as cryopreserved tumor fragments from the Division of Cancer Treatment Repository (Frederick, MD). GL261-HIgR51 mutant cells were stably transfected with the HSV-1 receptor, HIgR. The HIgR expression plasmid pCF18 was generated by cloning 2532 bp of HIgR cDNA into pCDNA.3.1 at the BstX1 and Not1 sites. GL261 mouse glioma cells were transfected with pCF18 using Lipofectamine (Invitrogen Corp., Carlsbad, CA, USA) as described previously. 26 Transfected cells were G418-selected, and HIgR expression verified by extent of lacZ expression after HSV-lacZ infection at low multiplicity of infection (MOI). Three monoclonal derivatives with high susceptibility to HSV-lacZ infection were isolated by limiting dilution. These cell lines were maintained in a 50:50 (v/v) mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's Nutrient Mixture F-12 (DMEM/F12) supplemented with 2.6 mM L-glutamine and 7% (v/v) fetal bovine serum.
Plasmids and viruses HSV-1 (F) is the origin of all engineered viruses in this series. 27 HSV mutant R3659 has been described previously. 28 Construction of M012, which expresses CD under transcriptional control of the early growth response-1 promoter (Egr-1), was identical to the construction of cytokine-expressing viruses R8306 (mIL-4) and R8308 (mIL-10), 16 and M002 (mIL-12). 17 HSV shuttle plasmid pRB4878, kindly provided by B Roizman (University of Chicago, Chicago, IL) has been described. 16 To construct pRB4878-CD, pCD2 (containing Escherichia coli CD) was purchased from ATCC (Rockville, MD; 40999). The coding region for CD was removed by digestion with EcoRI and BamHI, and 5 0 overhangs were filled with the Klenow fragment of DNA polymerase. Plasmid pRB4878 was digested with KpnI, ends blunted with T4 DNA polymerase and the CD gene was subcloned into the blunted KpnI site located between the Egr-1 promoter and hepatitis B polyadenylation sequences within pRB4878. M011 was constructed via homologous recombination of R3659 and pRB4878-CD, and tk gene repaired in M012. 27 Candidate CD-containing viruses were confirmed by Southern blot hybridization of BamHI-digested viral DNAs, using DNA probes specific for the CD insert, or for the repaired tk gene, as described previously. 17 
CD activity
To assess CD activity, conversion of tritiated 5-FC to 5-FU was measured as described previously. 29, 30 Vero cells were seeded at 3.5 Â 10 5 cells per well in six-well plates and incubated overnight. Cells were infected with R3659, HSV-1 (F), M012 or mock-infected, harvested at 40 h post-infection (h.p.i.) and pellets collected by centrifugation. Cells were resuspended in 10 ml of assay buffer (100 mM Tris, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, pH 7.8), and disrupted by repeated freeze/ thaw cycles and vortexing. Cell debris was removed, and 10 ml of supernates were combined with 10 ml (0.45 mCi, 250 mM) 5-FC-6-3 H and incubated (10 h, 371C). Ten microliters of each sample was mixed with 10 ml of unlabeled 4 mg/ml 5-FC þ 4 mg/ml 5-FU 'marker' solutions, spotted onto cellulose thin-layer chromatography (TLC) plates (Fisher Scientific, Atlanta, GA) and developed in a mixture of 1-butanol (86%) and water (14%). 5-FC and 5-FU bands were visualized using short-wave UV light, collected by scraping into scintillation vials, and radioactivity determined by a liquid scintillation counter. The radioactivity in the remaining 10 ml of each assay was also measured to determine the total recovery of radioactivity from the TLC plates. Percent conversion of 5-FC-6-3 H to 5-FU-6- . 31 CD activity in M012-infected Neuro-2a flank tumor homogenates was determined using a 10 ml (B1%) sample from tumor homogenates (see Replication assay above) combined with 10 ml (0.45 mCi) of Five days post-infection, viability was determined by addition of alamarBlue (Accumed International, West Lake, OH) and determining dye reduction (red color formation) by dual wavelength spectrophotometry at 562/ 590 nm on a Bio-Tek EL310 Plate reader (Winooski, VT). Absorbance values were normalized using the OD562/590 mean values for untreated cells as the 100% viable value. 13 Statistical analysis was performed using the Student's t-test.
To prepare conditioned media, 1.0 Â 10 4 Vero cells were infected with M012 at an MOI of 0, 0.1 or 1.0, with or without 1 mM 5-FC. At 24 or 48 h.p.i., supernates were harvested and added to the growth media of GL261 tumor cells that had been seeded at 1.0 Â 10 3 per well in 96-well plates. Increasing dilutions of M012-conditioned media (5 Â 10 À1 -5 Â 10
À6
) was added to the wells, and cells were incubated (7 days, 371C). Cell viability was quantified by the addition of alamarBlue and absorbance values were standardized as described previously. 14 Bystander cytotoxicity was assessed by M012 infection of GL261-HIgR51 cells grown in co-culture with GL261 cells. Varying ratios of GL261 and GL261-HiGR51 mutant cells were seeded at a total of 1.0 Â 10 4 cells in 96-well plates and grown overnight at 371C. On day 2, the mixed population of cells was infected with M012 at an MOI of 1.0 or 10, and supplemented with 0, 100, 500 or 1000 mM 5-FC. Five days after infection, cell viability was determined by alamarBlue assay as above. Absorbance values were standardized to 100% viable for the untreated cell population. h.p.i. as described previously. 16 Statistical analysis was performed after fitting the data to a generalized linear model.
M012 replication
To assess in vivo viral replication, flank tumors were established by injection of 3 Â 10 6 Neuro-2a cells into the right flanks of A/J strain mice, and grown to an approximate volume of 100 mm 3 . A measure of 5 Â 10 7 plaque forming units (PFU) in 50 ml of either M012 or R3659 was i.t. administered. Following infection, mice received 1 ml i.p. inoculations of saline alone or saline containing 10 mg 5-FC twice daily. On days 2, 4, 6 and 8 post-infection, tumors were resected, weighed and homogenized in sterile milk and DMEM (final dilution 1:5 w/v). Average weight of tumors was 0.3 g. Tumor homogenates were subjected to three freeze-thaw cycles (À801C, 371C), with 30 s pulse sonication after each cycle, and cell debris removed by centrifugation. Virus recovery from homogenates was determined by titration on Vero cells.
Animals
Specific pathogen-free female A/J strain mice at approximately 6 weeks of age were purchased (Charles River Laboratories, Wilmington, MA, USA). All animal studies were conducted in accordance with guidelines for animal use and care established by the University of Alabama at Birmingham Animal Resource Program and the Institutional Animal Care and Use Committee (protocol 97K03985).
Neurotoxicity
For the determination of M012 neurovirulence, virus injected into the right cerebral hemisphere of A/J mice at escalating doses (6.6 Â 10 6 , 2Â 10 7 and 6 Â 10 7 PFU) (three mice per group) in 10 ml total volume. 13 Beginning 1 day before virus injection, mice received 500 mg/kg 5-FC twice daily by i.p. administration for a total of 7 days.
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Mice were monitored for signs of toxicity. Maximum dose was limited by virus stock titer.
In vivo Neuro-2a flank tumor model One day before injection, Neuro-2a cells in log growth phase were fed with fresh growth medium. On the day of implantation, cells were harvested by trypsinization, pelleted and resuspended in serum-free DMEM such that the final concentration was 2.5 Â 10 7 cells/ml. For implantation, 0.2 ml of resuspended Neuro-2a cells were directly injected into the right flanks of A/J strain mice and allowed to grow until they reached approximately 100 mm 3 . Mice were evenly distributed among five treatment groups such that each group received tumorbearing mice that had overall similar average tumor sizes. One treatment group was injected i.t. with DMEM alone (50 ml). Two treatment groups each were injected with either R3659 or M012 virus at 1 Â 10 7 PFU in 50 ml. Beginning 1 day before virus injection, mice in one R3659 and one M002 treatment group were each administered 1 ml 500 mg/kg 5-FC twice daily i.p. for a total of 7 days. The control virus treatment groups received DMEM i.p. Mouse weights and tumor dimensions were determined biweekly. The data were analyzed for statistical significance using a linear mixed model, as described previously. 32 
Results
Construction of a recombinant HSV-1 containing the gene for bacterial CD The coding sequence for E. coli CD was introduced into both g 1 34.5 loci under transcriptional control of Egr-1 promoter, as described in Materials and methods. Recombinant HSV M011, M012 and the parent virus R3659 are illustrated (Figure 1 ). The recombinant, tk-negative, CD-expressing virus (M011) was confirmed by Southern blot hybridization (data not shown). The tk gene was restored within M011 and 12 candidate tkrepaired clones were similarly screened by Southern blot hybridization. The candidate clone with highest CD activity was chosen for all subsequent studies and designated M012. M012 was further plaque purified in Vero cells to eliminate any residual tk-HSV-CD viruses. The presence of the repaired tk gene in M012, as well as the presence of CD, was also confirmed by Southern analysis (data not shown).
CD activity after infection with M012
To evaluate the biologic activity of the CD gene product produced by M012, conversion of tritiated 5-FC to 5-FU was measured. Vero cells were mock infected, or infected with wild-type HSV-1(F), parent virus R3659 or M012 at increasing MOI, harvested at 40 h.p.i., and incubated with tritiated 5-FC, as described in Materials and methods. Reaction products were resolved by TLC and production of 5-FU-6- Table 1) . CD produced by M012 was able to convert high concentrations (250 mM) of 5-FC with a mean conversion of 33% of tritiated 5-FC to 5-FU at 48 h.p.i. (range 27-50%). Analysis of CD activity between the two treatment groups and compared over time shows statistically significant differences between the two groups (Po0.0001, general linear model). HSV-1 expressing CD for brain tumor therapy MB Guffey et al increased toxicity to Neuro-2a cells infected by M012 in a prodrug dose-dependent manner (Figure 3 ). With 5-FC concentrations as low as 100 mM, a significantly greater cytotoxic effect was seen in M012-infected cells infected at lower MOI when compared to R3659 infected at a higher MOI (Po0.001). At 500 mM 5-FC, at all MOIs tested, M012 was more effective at killing Neuro-2a cells than R3659 (Po0.001). At 1000 mM 5-FC, tumor cells were less viable than with lower concentrations of 5-FC, but the additional M012 effect over R3659 remained demonstrable (for R3659 MOI ¼ 5.0, Po0.001, and for R3659 MOI ¼ 1.0, Po0.032). There appeared to be a greater M012/5-FC effect at higher MOI, perhaps owing to increased CD expression. Under conditions where direct viral lytic effects are limited (as demonstrated by minimal cytolytic effect at 0 mM 5-FC independent of MOI), prodrug-mediated cytotoxicity is more apparent at higher MOI of M012. M012 also showed an effect at an MOI as low as 0.1, but this effect was not seen until the concentration of 5-FC was 500 mM or greater (data not shown).
'Conditioned media' from Vero cells infected with M012 and given 5-FC is toxic to GL261 glioma cells
We next determined whether M012-infected cells would produce a diffusible cytotoxin in the presence of 5-FC capable of killing tumor cells. Vero cells were infected with M012 in the presence or absence of 1 mM 5-FC. At 24 or 48 h.p.i., 'conditioned media' were collected from M012-infected cells, which, when grown in the presence of 5-FC, should contain both 5-FU and progeny virions. To demonstrate 5-FU cytotoxicity independent of cytotoxicity owing to direct cell lysis by virus, M012-conditioned media was tested on the HSV-1-resistant GL261 murine glioma cells. This cell line is resistant to infection by both wild-type and g 1 34.5 mutant HSV-1, even at high MOI (1000).
33 GL261 tumor cells were inoculated with the M012-conditioned media at dilutions ranging from 5 Â 10 À1 to 5 Â 10 À6 of the original concentration, and grown for 7 days. Cell viability was assayed by alamarBlue as described previously.
14 Supernates were collected from M012 or mock-infected cells cultured with or without 5-FC. Media from M012-infected Vero cells grown in the presence of 5-FC killed GL261 tumor cells, whereas the media collected from infected cells grown in the absence of 5-FC did not. At both 24 (data not shown) and 48 h.p.i. (Figure 4) , a CD/5-FC effect was observed. For GL261 cells exposed to the 5-FC/M012 'conditioned' medium, there was a greater cytotoxic effect observed at the later time point (48 h). Additionally, M012/5-FC 'conditioned' medium produced a more dramatic effect on tumor inhibition at 48 h when obtained from cells 
GL261 cells co-cultured with GL261-HIgR cells demonstrate bystander killing
To improve the efficiency of HSV-1 infection of GL261 cells, these cells were stably transfected with a plasmid expressing the HSV entry receptor nectin-1 (HIgR). 34 These cells, referred to herein as GL261-HIgR, exhibited similar growth characteristics to the parent cell line GL261 and can be infected by HSV-1, similar to human glioma cells (Gillespie GY, unpublished results). Neurovirulence M012 neurovirulence of the CD-expressing virus (PFU/ LD 50 ) following intracerebral inoculation was assessed as follows. HSV-susceptible A/J mice were injected intracerebrally with escalating doses (6.6 Â 10 6 , 2 Â 10 7 and 6 Â 10 7 PFU) of M012 (three mice/group) in 10 ml total volume. Beginning 1 day before virus injection, 1 ml of 5-FC (10 mg/ml) was administered twice daily for a total of 7 days. No deaths occurred in any of the groups after monitoring the mice for 30 days (data not shown). Furthermore, none of the animals appeared ill, even at the highest dose tested (limited by the titer of the virus stock). Thus, the maximum tolerated dose (PFU/LD50) of M012 combined with 5-FC administration is 46 Â 10 7 PFU in A/J strain mice. Similar findings were seen in the absence of 5-FC administration.
M012 combined with i.p. administration of 5-FC significantly reduces growth of neuroblastoma flank tumors We next tested whether treatment of subcutaneous flank tumors in a syngeneic murine tumor model with M012 combined with 5-FC administered by i.p. injection resulted in more effective tumor reduction than treatment with virus alone. Five treatment cohorts, each containing six tumor-bearing mice randomly distributed, were established. The control group received i.t. injection of 50 ml DMEM alone. Two treatment groups each received either 1 Â 10 7 PFU R3659 or M012, and were also administered 5-FC twice daily i.p. as described in Materials and methods. The final two treatment groups also received the same dose of either R3659 or M012, but instead of 5-FC, received DMEM i.p. twice daily. Tumor burden was monitored for 18 days, with measurements twice a week. At each time point, the percent increase over the initial tumor volume was calculated for each of the tumors in a given treatment group, and the average percent increase was plotted ( Figure 6 ). The cohort receiving M012 in combination with 5-FC administration significantly reduced tumor volume versus the treatment groups receiving vehicle only (Po0.0001), and versus the groups administered R3659 with (P ¼ 0.046) or without (P ¼ 0.0003) 5-FC. Additionally, the average tumor volume of the M012 only treatment cohort was 862 mm 3 larger than the average tumor volume of the M012 þ 5-FC treatment cohort, which approached statistical significance (P ¼ 0.0795).
To determine the reproducibility of these results, we conducted a second experiment using the same cohorts (n ¼ 6/cohort) and treatment regimen as described above. As with the first experiment, the efficacy of 5-FC administration in combination with M012 treatment became more pronounced over time, such that by day 14 tumor burden in this group versus average tumor burden in the cohort receiving M012 alone was significantly different (P ¼ 0.0269, see Table 2 ). In comparison, there was no significant difference (P ¼ 0.1996) in tumor growth rates for animals treated with i.t. R3659 with i.p. 5-FC or with R3659 alone (data not shown). 
Bystander Cytotoxicity
Statistical analyses of flank tumor studies
The outcome of interest in the experiment is the effect of the therapy on volume of the tumor. As the mice in each treatment group have different starting tumor volumes, the volume after treatment was expressed as a proportion of the volume on day 0. A linear mixed model with volume as the outcome variable, and an autoregressive covariance structure was then fit to the data. The predictors in the model were treatment, time and the interaction between these. An examination of the residual plots suggested that this model was adequate. Time and the interaction between treatment and time were significant predictors of the rate of change in volume. The significance of the interaction term suggests that the average rate of change of volume over time was a function of the treatment group. Table 2 indicates the statistically significant differences between the groups at the various time points for the growth curves for both Experiment 1 ( Figure 6 data) and Experiment 2 (growth curves not shown).
Discussion
Systemic 5-FU is the mainstay of chemotherapy of several malignancies (colon, pancreatic and other GI carcino- 39 We have reported the sensitivity of human glioma cell lines to 5-FU. 40 I.t. delivery of genes encoding prodrug-activating enzymes, an approach termed GDEPT 41 or molecular chemotherapy, 42 has the potential to become a powerful alternative method of drug delivery. In particular, the GDEPT combination of CD (EC 3.5.4.1) and 5-FC may be used to circumvent the pharmacokinetic limitations of systemic 5-FU. In this system, non-toxic anti-fungal 5-FC is deaminated to the potent antitumor agent 5-FU within tumor cells expressing CD.
Because of the clinical implications of the significant bystander effect achieved by the CD/5-FC system, multiple gene therapy protocols have been developed utilizing CD, including retroviral, 43 vaccinia, 44,45 adenovirus 46 and HSV 23 vectors. Studies of the observed CD/5FC 'bystander effect' have shown it to be more effective compared to the HSV-tk/ganciclovir system. 23, 46, 47 A combination of these two suicide genes introduced within a replication-competent adenovirus with radiotherapy was found to significantly augment the antitumor activity of these vectors in a murine cervical carcinoma model. 48 Another replication-selective adenovirus that expresses CD for anticancer therapy is ONYX-305. 49 In this construct, the E3 adenovirus death protein (ADP) was deleted and replaced with CD. Cells infected with ADPdeleted adenovirus vectors live longer, thus allowing for extended protein synthesis, including synthesis of foreign proteins like CD from transgenes introduced into the virus. Efficacy of a gene therapy suicide gene-prodrug model using a replication-defective adenoviral vector has been demonstrated in patients with operable primary or recurrent glioma. 50 The CD system has been studied in two different HSV models. One study demonstrated the efficacy of a replicative virus deleted for the large subunit of ribonucleotide reductase that expressed CD in colorectal tumors. 51 Other studies suggested the possible benefits of non-replicative HSV systems that express CD for the experimental treatment of glioma. 52 The current study describes for the first time a conditionally replicating, Dg 1 34.5 HSV vector engineered to express CD, M012, which is similar in construction to mutant oncolytic HSV already used safely for intracranial administration in humans. Conditionally replicating HSV mutants that express CD have been reported previously by other groups. Nakamura et al. 51 utilized an HSV mutant in which the U L 39 gene (encoding the ICP6 protein, or viral large ribonucleotide reductase subunit) was disrupted by the introduction of the gene for yeast CD. This vector was used for the treatment of colon carcinoma metastases of the liver, and was administered via the portal vein. However, this vector contains intact copies of the g 1 34.5 gene, and thus is not safe for the treatment of malignancies arising in the brain.
As expected, addition of 5-FU to the growth medium reduced both R3659 and M012 replication in Neuro-2a cells in culture. The addition of 5-FC had no effect on R3659 replication, whereas by 48 h M012 replication was reduced by 1 log in the presence of 5-FC and continued to decrease over time. Although Nakamura et al. 51 reported that addition of 5-FC had minimal effect on replication of their ICP6-deleted, CD-expressing HSV in HT29 human colon carcinoma cells, they only looked at a single time point (40 h.p.i.) and the concentration of 5-FC administered was 20 mg/ml as compared to 65 mg/ml used in this study. The difference in effect on replication of the HSV mutants by addition of 5-FC could also be cell line or species specific. This is supported by our observation that a decrease in M012 replication was also seen in the mixed murine glioma cell model, using HSV-resistant GL261 cells and HSV-sensitive GL261-HIgR51 cells, but to a lesser extent (JN Parker and JM Markert, unpublished data).
Increased cytotoxic effects were seen with increasing MOI of M012 in the presence of 5-FC, as assayed on Neuro-2a cells. Similarly, increasing the concentration of 5-FC increased the cytotoxic effects of this virus at a constant MOI; these effects were not seen with R3659-infected cells. Thus, M012 therapy of tumor cells when administered in conjunction with 5-FC produces an increase in antitumor effects in our model system.
The lack of increased cytotoxicity produced when tumor cells were treated with R3659 and 5-FC indicates that a direct viral-5-FC interaction is not responsible for an increased cytotoxicity in infected cells. To rule out that increased cytotoxicity was owing to a direct interaction of the 5-FU on cells infected with virus alone, for example, an increase in the apoptotic rate of infected cells, two separate experiments were performed. In the first experiment, media were collected from cultures of Vero cells infected with M012 and added to HSV-resistant GL261 cells. In the second experiment, HSV-resistant GL261 cells were co-cultured with varying ratios of GL261-HIgR51 cells. Both studies demonstrated that a non-viral cytotoxic agent was present in the media of cells infected with M012 and treated with 5-FC. This is consistent with the known bystander properties of diffusible 5-FU produced by CD in M012-infected tumor cells treated with 5-FC on adjacent, uninfected cells.
We chose to use the Neuro-2a spontaneous neuroblastoma of A/J mouse origin for a number of reasons. First, it has been previously shown to be susceptible to HSV-1 infection. 53 Second, Neuro-2a is one of several clonal derivatives of the C-1300 spontaneous neuroblastoma of A/J mice, and has been used previously for evaluating multiple therapeutic modalities. 54 Finally, the tumor exhibits low immunogenicity, including low levels of major histocompatibility comlex (MHC) I, MHC II and B7.1 expression, and is thus a stringent test for preclinical models of antitumor immunotherapy. 17 In addition, the lack of immunogenicity of this tumor limits the possibility of an artificial immune response contributing to the effect seen.
The statistical method employed for analysis indicated that by 18 days following treatment, the M012 plus 5-FC therapy did significantly reduce the overall mean tumor volume as compared to therapy with the parent virus plus 5-FC. In the repeat experiment, animals were forced to be killed after 14 days, which prevented a direct comparison between these two groups at that time point. Of note, however, is that in the first experiment, statistically significant reduction in tumor burden of the M012 þ 5-FC treatment group versus the R3659 þ 5-FC treatment group was not observed until day 18.
Although increased efficacy is seen in the in vitro and in vivo models examined, a number of questions remain to be addressed. These include an understanding of the extent of the viral distribution within the tumor, the optimal timing of 5-FC administration and the amount of prodrug conversion within the treated tumors. Those studies are currently underway, as are studies to determine the efficacy of this therapy in experimental murine models of glioma.
In summary, we have constructed an HSV-1 vector that is potentially safe for administration into human brain tumors and expresses functional CD. This virus produces increased tumoricidal effects in in vitro studies of malignant brain tumors; these increased effects are seen in the presence of 5-FC. Both in vitro and in vivo production of 5-FU, as well as a bystander effect, was demonstrated in these models. We further demonstrated that direct intracranial injection of M012 with 5-FC administered concomitantly was not neurotoxic at doses up to 6 Â 10 7 PFU in HSV-susceptible A/J strain mice. Finally, treatment of Neuro-2a flank tumors established in A/J mice with M012 combined with 5-FC administration had significant reduction of tumor burden versus those tumors treated with R3659 combined with 5-FC, or treated with M012 alone. These promising studies support further examination of M012 in conjunction with 5-FC administration in preclinical models of malignant brain tumors.
